Evidence map›Paper›PMID 37056371›Full record

ArticleCell reports methods2023

Diagnostic TR-FRET assays for detection of antibodies in patient samples.

Hong Yue, Radosław P Nowak, Daan Overwijn, N Connor Payne, Stephanie Fischinger, Caroline Atyeo, Evan C Lam, Kerri St Denis, Lauren K Brais, Yoshinobu Konishi and 13 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports methods, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.2field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

23 authors at 5 institutions in 1 country.

Hong YueDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Radosław P NowakDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Daan OverwijnDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
N Connor PayneDepartment of Chemistry & Chemical Biology, Harvard University, Cambridge, MA 02138, USA.
Stephanie FischingerRagon Institute of MGH, Massachusetts Institute of Technology (MIT), and Harvard, Cambridge, MA 02139, USA.
Caroline AtyeoRagon Institute of MGH, Massachusetts Institute of Technology (MIT), and Harvard, Cambridge, MA 02139, USA.
Evan C LamRagon Institute of MGH, Massachusetts Institute of Technology (MIT), and Harvard, Cambridge, MA 02139, USA.
Kerri St DenisRagon Institute of MGH, Massachusetts Institute of Technology (MIT), and Harvard, Cambridge, MA 02139, USA.
Lauren K BraisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Yoshinobu KonishiDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Romanos Sklavenitis-PistofidisDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Lindsey R BadenDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
Eric J NillesDepartment of Emergency Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Elizabeth W KarlsonDepartment of Medicine, Brigham and Women's Hospital, Boston, MA 02115, USA.
Xu G YuRagon Institute of MGH, Massachusetts Institute of Technology (MIT), and Harvard, Cambridge, MA 02139, USA.
Jonathan Z LiDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
Ann E WoolleyDivision of Infectious Diseases, Brigham and Women's Hospital, Boston, MA 02115, USA.
Irene M GhobrialDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Jeffrey A MeyerhardtDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Alejandro B BalazsRagon Institute of MGH, Massachusetts Institute of Technology (MIT), and Harvard, Cambridge, MA 02139, USA.
Galit AlterRagon Institute of MGH, Massachusetts Institute of Technology (MIT), and Harvard, Cambridge, MA 02139, USA.
Ralph MazitschekCenter for Systems Biology, Massachusetts General Hospital (MGH), Boston, MA 02114, USA.
Eric S FischerDepartment of Cancer Biology, Dana-Farber Cancer Institute, Boston, MA 02215, USA.
Ragon Institute of MGH, MIT and Harvard · USBrigham and Women's Hospital · USHarvard University · USBroad Institute · USDana-Farber Cancer Institute · US

Funding

The molecular basis of IMiD induced neo-substrate recruitment to the CRL4CRBN ubiquitin E3 ligase.R01CA214608 · NCI · DANA-FARBER CANCER INST · PI Eric Sebastian Fischer · 2017 to 2026
$4.0M
NCI NIH HHS R01 CA214608
6 · The paper itself

Abstract

Serological assays are important diagnostic tools for surveying exposure to the pathogen, monitoring immune response post vaccination, and managing spread of the infectious agent among the population. Current serological laboratory assays are often limited because they require the use of specialized laboratory technology and/or work with a limited number of sample types. Here, we evaluate an alternative by developing time-resolved Förster resonance energy transfer (TR-FRET) homogeneous assays that exhibited exceptional versatility, scalability, and sensitivity and outperformed or matched currently used strategies in terms of sensitivity, specificity, and precision. We validated the performance of the assays measuring total immunoglobulin G (IgG) levels; antibodies against severe acute respiratory syndrome coronavirus (SARS-CoV) or Middle Eastern respiratory syndrome (MERS)-CoV spike (S) protein; and SARS-CoV-2 S and nucleocapsid (N) proteins and applied it to several large sample sets and real-world applications. We further established a TR-FRET-based ACE2-S competition assay to assess the neutralization propensity of the antibodies. Overall, these TR-FRET-based serological assays can be rapidly extended to other antigens and are compatible with commonly used plate readers.

Indexed as

COVID-19SARS-CoV-2Antibodies, ViralCOVID-19 TestingFluorescence Resonance Energy TransferHumansNucleocapsidAntibodies, ViralCoraFluorneutralization assayserological testingTR-FRET assaysvaccine efficacy studies

Identifiers

PMID37056371
PMCPMC10088089
OpenAlexW4321378866

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.